Last reviewed · How we verify
zuclopentixol
At a glance
| Generic name | zuclopentixol |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach (PHASE2)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Antipsychotics and Risk of Hyperglycemic Emergencies
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zuclopentixol CI brief — competitive landscape report
- zuclopentixol updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI